Seronegative occult hepatitis C infection among hemodialysis patients: A prevalence study.
Adult
Aged
Aged, 80 and over
Cross-Sectional Studies
Female
Genotype
Hepacivirus
/ genetics
Hepatitis C
/ blood
Humans
Leukocytes, Mononuclear
/ virology
Male
Middle Aged
Prevalence
RNA, Viral
/ blood
Renal Dialysis
Reverse Transcriptase Polymerase Chain Reaction
Serologic Tests
/ methods
Young Adult
hemodialysis
nested reverse transcriptase-polymerase chain reaction
occult hepatitis C virus infection
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
07
04
2020
revised:
24
05
2020
accepted:
04
06
2020
pubmed:
9
6
2020
medline:
21
10
2021
entrez:
9
6
2020
Statut:
ppublish
Résumé
The aim of this study was to investigate the prevalence of occult hepatitis C virus (HCV) infection (OCI) among HD patients. Blood samples were taken from 79 HD patients and their sera were evaluated for the presence of anti-HCV. Both the sera and peripheral blood mononuclear cells (PBMCs) were then checked for HCV RNA by nested reverse transcriptase-polymerase chain reaction. Anti-HCV was positive among 4/79 (5.1%) of the patients. From 75 patients who were negative for anti-HCV, 71 (94.7%) patients were also negative for HCV RNA in sera samples but five of them were positive for HCV RNA in PBMCs. Totally, out of 79 patients, HCV RNA was detected in PBMCs of five (6.3%) patients, indicating that these patients had OCI. No significant difference was observed between the frequency of OCI and gender (P-value = .6). HCV genotype in all five cases of OCI was genotype 3a. Our study showed prevalence rate of 6.3% OCI infection in HD patients. Regarding the serious complications and the clinical importance of OCI in HD patients, sensitive diagnostic methods for identifying HCV RNA in the PBMCs should be implemented for all HD patients.
Identifiants
pubmed: 32510846
doi: 10.1111/1744-9987.13535
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
218-224Subventions
Organisme : Ahvaz Jundishapur University of Medical Sciences
ID : grant no: OG-9744
Informations de copyright
© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Samiei RN, Shokri S, Mahmoudvand S, et al. Occult hepatitis B virus infection among hemodialysis patients. J Biol Res. 2018;91(2):7516.
Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol. 2008;18(2):97-115.
Mahmoudvand S, Shokri S, Taherkhani R, Farshadpour F. Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma. World J Gastroenterol. 2019;25(1):42-58.
Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F, Jalalian FA. Complexity on modulation of NF-κB pathways by hepatitis B and C: A double-edged sword in hepatocarcinogenesis. J Cell Physiol. 2019;234(9):14734-14742.
Austria A, Wu GY. Occult hepatitis C virus infection: A review. J Clin Transl Hepatol. 2018;6(2):155-160.
Rezaee-Zavareh MS, Hadi R, Karimi-Sari H, et al. Occult HCV infection: The current state of knowledge. Iran Red Crescent Med J. 2015;17(11):e34181.
Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Intern Med. 2015;3(3):93-105.
Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51(4):981-999.
Wreghitt T. Blood-borne virus infections in dialysis units-A review. Rev Med Virol. 1999;9(2):101-109.
Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World J Gastroenterol. 2017;23(1):151-166.
Guo X, Zhong J-Y, Li J-W. Hepatitis C virus infection and vaccine development. J Clin Exp Hepatol. 2018;8(2):195-204.
Miyazaki R, Miyagi K. Effect and safety of daclatasvir-asunaprevir combination therapy for chronic hepatitis C virus genotype 1b-infected patients on hemodialysis. Ther Apher Dial. 2016;20(5):462-467.
Mekky MA, Sayed HI, Abdelmalek MO, et al. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: A multi-center study. Infect Drug Resist. 2019;12:273-279.
Lee WM, Polson JE, Carney DS, Sahin B, Gale M Jr. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: Evidence for an occult viral reservoir. J Infect Dis. 2005;192(6):1088-1092.
Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41(1):106-114.
Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004;78(11):5867-5874.
Etik DO, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: A review. World J Hepatol. 2015;7(6):885-895.
Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol. 2010;82(9):1554-1559.
Radmehr H, Makvandi M, Samarbafzadeh A, et al. Prevalence of hepatitis C virus genotype 3a in patients with Hodgkin and non-Hodgkin lymphoma. Iran J Microbiol. 2016;8(6):389-394.
Zare F, Fattahi MR, Sepehrimanesh M, Safarpour AR. Economic burden of hepatitis C virus infection in different stages of disease: A report from southern Iran. Hepat Mon. 2016;16(4):e32654.
Blackard JT, Kong L, Lombardi A, Homann D, Hammerstad SS, Tomer Y. A preliminary analysis of hepatitis C virus in pancreatic islet cells. Virol J. 2017;14(1):237.
Abdelmoemen G, Khodeir SA, Abou-Saif S, Kobtan A, Abd-Elsalam S. Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: A single-center study. Environ Sci Pollut Res. 2018;25(6):5459-5464.
Bozkurt I, Aygen B, Gökahmetoglu S, Yildiz O. Hepatitis C and occult hepatitis C infection among hemodialysis patients from Central Anatolia. J Pure Appl Microbiol. 2014;8:435-440.
Abdelrahim SS, Khairy R, Esmail MAM, Ragab M, Abdel-Hamid M, Abdelwahab SF. Occult hepatitis C virus infection among Egyptian hemodialysis patients. J Med Virol. 2016;88(8):1388-1393.
El-Shishtawy S, Sherif N, Abdallh E, et al. Occult hepatitis C virus infection in hemodialysis patients; single center study. Electron Physician. 2015;7(8):1619-1625.
Barril G, Castillo I, Arenas MD, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol. 2008;19(12):2288-2292.
Gong G-Z, Lai L-Y, Jiang Y-F, He Y, Su X-S. HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol. 2003;9(2):291-294.
Meier V, Mihm S, Braun PW, Ramadori G. HCV-RNA positivity in peripheral blood mononuclear cells of patients with chronic HCV infection: Does it really mean viral replication? World J Gastroenterol. 2001;7(2):228-234.
Pham TN, MacParland SA, Coffin CS, Lee SS, Bursey FR, Michalak TI. Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol. 2005;86(3):657-666.
Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: Systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8(1):1-17.
Mahajan R, Midha V, Goyal O, et al. Clinical profile of hepatitis C virus infection in a developing country: India. J Gastroenterol Hepatol. 2018;33(4):926-933.
Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176.
Botheju WS, Zghyer F, Mahmud S, Terlikbayeva A, El-Bassel N, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses. Sci Rep. 2019;9(1):1-15.
Adland E, Jesuthasan G, Downs L, et al. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. BMC Infect Dis. 2018;18(1):461.
Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526-1533.
Marwaha N, Sachdev S. Current testing strategies for hepatitis C virus infection in blood donors and the way forward. World J Gastroenterol. 2014;20(11):2948-2954.
Akkaya O, Kiyici M, Yilmaz Y, Ulukaya E, Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol. 2007;13(41):5481.
Sette LHBC, de Almeida Lopes EP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: A comprehensive review. Clinics. 2014;69(4):271-278.
Akiba T, Hora K, Imawari M, et al. 2011 Japanese Society for Dialysis Therapy guidelines for the treatment of hepatitis C virus infection in dialysis patients. Ther Apher Dial. 2012;16(4):289-310.
Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, et al. Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. Open Forum Infectious Diseases. 2019;6(3). https://doi.org/10.1093/ofid/ofz076.
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824-7840.
Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87.
Spearman CW, Geoffrey MD, Margaret H, Sonderup M. Hepatitis C. Lancet. 2019;394(10207):1451-1466.
Sefidi FJ, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon. 2013;13(1):e7991.
Khodabandehloo M, Roshani D. Prevalence of hepatitis C virus genotypes in Iranian patients: A systematic review and meta-analysis. Hepat Mon. 2014;14(12):e22915.